What happened with DGX today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Physicians send patients and samples to Quest Diagnostics, which collects specimens through its patient-access network, tests them in laboratories and reports results to guide care. Routine testing and related services account for most revenue; specialized genetic and other complex tests contribute a substantial share. It also examines tissue and cells for cancer and other conditions, and provides testing and laboratory-management services to hospitals. The business is predominantly in the United States, with LifeLabs operating in Canada.
The clinician ordering a test is often not the payer. Health insurers and government programs such as Medicare and Medicaid pay for most services, usually per test; some insurance contracts instead pay a fixed monthly amount per covered member. Hospitals and other institutional customers also pay Quest directly, while patients pay for self-requested tests and their share of medical bills.
The business depends on physician referrals and on insurers’ and government programs’ coverage decisions and payment rates. Health plans collectively supply an important share of revenue, but no single plan dominates. Quest must maintain laboratory licenses and certifications and comply with rules governing billing, physician relationships and patient privacy.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Labcorp is Quest’s largest commercial laboratory rival, competing through national networks for routine and specialty tests ordered by physicians and hospitals and paid for by patients, clients and health insurers. Watch Labcorp’s Dx testing business rather than its drug-development laboratory business for signals about the test volumes and reimbursement rates that also matter to Quest.
NeoGenomics competes with Quest for cancer pathology and genomic testing work from physician practices and hospital laboratories. Its cancer testing and expert interpretation services for community pathologists and oncologists are the part to watch for competition with Quest, rather than its pharmaceutical-company work.
Myriad Genetics competes with Quest in cancer testing, prenatal and carrier screening, and mental-health molecular testing that helps guide treatment. Its Oncology, Women’s Health and Mental Health testing businesses—including GeneSight in mental health—show where that competition plays out.
Fulgent Genetics competes with Quest in examining tissue and cell samples for disease, precision diagnostics and specialized cancer testing, earning laboratory revenue from testing and physicians’ interpretation of results. Its laboratory-services results are the relevant comparison for Quest, not its separate therapeutic-development business.
Natera competes with Quest in prenatal and hereditary cancer testing and in blood tests used to monitor cancer, selling tests directly and through laboratory and distribution partners. Adoption of its women’s-health tests and personalized blood-based cancer monitoring is the clearest area to watch for this overlap, rather than its transplant-testing business.
Guardant Health competes with Quest in blood tests that help select cancer treatment and detect cancer remaining after treatment. Watch its oncology testing revenue and U.S. Medicare and private-insurer coverage for qualifying Guardant360 and Guardant Reveal patients, rather than treating its screening or biopharma revenue as the same competitive signal.
Tempus AI competes with Quest for cancer, hereditary and molecular pathology tests ordered by healthcare providers. Its Diagnostics business is the relevant competitive read-through; licensing data and selling applications to life sciences customers is a separate business.
Caris Life Sciences competes with Quest to provide physicians with molecular cancer profiles and blood-based monitoring for residual disease. Physician use of its tissue-based MI Profile and blood-based Caris Assure profiling services is a concrete window into the profiling competition, distinct from its research and biopharma services.
BillionToOne competes with Quest for physicians’ orders for prenatal tests using maternal blood rather than an invasive procedure, and for comprehensive carrier screening. Watch its UNITY prenatal business and prenatal sales-team expansion for this competition, rather than its Northstar tests for late-stage cancer.
Quest Diagnostics Inc. earningsThis company
Quest Diagnostics’ report will show whether its testing business can grow through more tests generated organically and more revenue per test order, rather than relying on acquisitions to expand.
Read organic test-volume growth alongside revenue per requisition, or test order; organic growth excludes the contribution from acquisitions. If both rise, more growth is coming from the existing business and the revenue generated by each order is holding up. If volume is weak or revenue fails to keep pace, the growth base is less convincing. Then check operating margin: rising volume and revenue with a steady margin suggest costs are keeping pace, while a falling margin means labor, supplies or other operating costs are absorbing some of the growth. The conclusion is whether Quest’s core testing business is expanding and turning that growth into profit.
Labcorp Holdings Inc. earningsLH
Labcorp’s diagnostic testing business will show whether physician- and hospital-ordered test demand and payer payments are helping or constraining the work it shares with Quest.
Look at Labcorp’s Dx testing volume and revenue together, alongside any discussion of payer reimbursement or payment pressure. If both volume and revenue are strong and payment pressure is not worsening, demand from the physicians and hospitals both companies pursue looks supportive, without pricing pressure yet offsetting it. If volume grows but revenue is weak, or reimbursement pressure increases, more tests may not bring in proportionate revenue and Quest could face similar payer pressure. Labcorp’s business mix and market share differ, so this is an industry signal, not a substitute for Quest’s own results.
JOLTs Job Openings (Sep)
Job openings track employers’ demand for workers; stronger demand can make it harder for Quest Diagnostics to hire phlebotomists and specimen processors and raise the labor costs of running its testing services.
Expected7.0MLast release7.079M
If it comes in above expectations
More openings can intensify competition for the phlebotomists and specimen processors Quest needs, making hiring harder and pushing up staffing costs that weigh on operating margins.
If it comes in below expectations
If the reading is below the 7.0M estimate, it is below the previous 7.079M. Fewer openings can ease competition for phlebotomists and specimen processors, potentially making hiring easier and slowing the rise in staffing costs that weigh on Quest’s operating margins.
Non Farm Payrolls (Oct)
Payrolls count jobs added or lost across the economy; stronger job growth can intensify competition for the phlebotomists and specimen processors Quest Diagnostics needs to run its testing services, raising hiring and compensation costs.
More jobs added would suggest a stronger labor market and potentially tougher competition for Quest’s constrained supply of laboratory staff, with higher hiring and pay costs; fewer jobs added would suggest weaker demand and possible relief from that cost pressure.
